Business Wire

YOKOGAWA/SENSIRE

6.6.2019 08:02:06 CEST | Business Wire | Press release

Share
Yokogawa Takes Strategic Stake in Finnish Company Sensire Ltd. to Pursue Collaboration in Cold Chain Monitoring

Yokogawa Electric Corporation (TOKYO:6841) and Finland-based Sensire Ltd. announce that they have reached an agreement for Yokogawa to take a €6 million stake in Sensire and to begin collaborating in the cold chain monitoring field. Through this initiative, both companies aim to develop and provide new services that combine Yokogawa’s Industrial Internet of Things (IIoT) architecture, subscription-based IIoT services being developed by its amnimo Inc. subsidiary, and Sensire’s cold chain temperature monitoring solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005285/en/

Demand for solutions that facilitate the temperature-controlled transportation of perishable items from the point of origin to the point of consumption is on the rise, and this need is particularly acute with pharmaceutical and food products that require strict temperature control.

Sensire Ltd. offers a full range of specialized temperature monitoring solutions mainly for the cold chain. Sensire’s compact and power efficient temperature sensors collect and transmit temperature data to the cloud for access from PCs and mobile devices. Supporting a range of wireless communication protocols suitable for land, sea, and air transport applications, Sensire’s solutions ensure access to continuous real-time monitoring data that delivers vital quality and compliance information when and where it is needed.

Yokogawa is developing a cloud-based IIoT architecture in collaboration with Microsoft Corporation of the United States, and based on this is starting to provide solutions for the remote monitoring of physical quantities. In addition, Yokogawa’s amnimo Inc. business unit is developing IIoT services that use this architecture to provide access to data from not only manufacturing plants but also many other types of facilities and situations, with the aim of delivering subscription-based Measurement as a Service (MaaS).

Having taken a 35.2% stake in Sensire, Yokogawa is now this company’s largest shareholder. Utilizing Yokogawa’s know-how and global network, the two companies will work together to develop new temperature monitoring solutions for the cold chain and other logistics services, and expand this business.

Tsuyoshi Abe, a Yokogawa senior vice president and head of the company’s Marketing Headquarters, commented, “Under its Transformation 2020 mid-term business plan, Yokogawa is now exploring new business models such as recurring revenue while also aiming to expand its business in the pharmaceutical and food fields. I am convinced that Sensire’s solutions will accelerate these efforts, and I trust that we will be able to deliver new value to applications where precise temperature control is critical by combining the technologies of both companies.”

JP Asikainen, founder and CEO of Sensire, added, “I believe that this collaboration with Yokogawa will provide us an opportunity to expand the business globally and ensure the transition to the next-generation of cloud architecture. We look forward to making the latest and best cold chain solutions available to customers in a broader range of industries and applications.”

Related links
amnimo Inc .

About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com .

About Sensire
Sensire Ltd., founded in 2007 by CEO JP Asikainen, offers comprehensive wireless and automatic real-time monitoring products that serve the globally vital climate-controlled chain. The IoT tech company’s solutions help deliver better safety and quality in various cold chain operations from food industry applications to pharmaceutical logistics, as well as in many climate-sensitive healthcare premises. Sensire is committed to being the leading innovator in cold chain IoT technology in order to offer best-in-class products and services to its customers. Headquartered in Joensuu, Finland, the company turnover in FY2018 was EUR 1.5 million. For more information, visit www.sensire.com

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation, Sensire Ltd., or their respective holders.

Contact:

Yokogawa Electric Corporation Philip Lewis Public Relations Manager Email: Yokogawa-pr@cs.jp.yokogawa.com 2-9-32 Nakacho Musashino-shi Tokyo Japan 180-8750 Tel: +81 422-52-5530

Link:

ClickThru

Social Media:

https://www.facebook.com/Yokogawa-127328307136/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye